2020
Anti-Müllerian hormone as a qualitative marker - or just quantity?
Kotlyar A, Seifer DB. Anti-Müllerian hormone as a qualitative marker - or just quantity? Current Opinion In Obstetrics & Gynecology 2020, 32: 219-226. PMID: 32205525, DOI: 10.1097/gco.0000000000000623.Peer-Reviewed Original ResearchMeSH KeywordsAbortion, SpontaneousAnti-Mullerian HormoneBiomarkersFemaleFertilization in VitroHumansOocytesOvarian ReservePolycystic Ovary SyndromePregnancyPrimary Ovarian InsufficiencyConceptsAnti-Müllerian hormoneOvarian reserve testingClinical pregnancy rateLive birth rateOnset of menopausePremature ovarian insufficiencyNumber of oocytesSignificant predictive valueAMH levelsFertilization cyclesPregnancy rateOvarian insufficiencyIntracycle variabilityOocyte qualityPredictive valueEarly folliclesFetal trisomiesHormoneReproductive technologiesRiskQualitative markersSmall interMenopauseInsufficiencyFollicles
2014
Assisted hatching and intracytoplasmic sperm injection are not associated with improved outcomes in assisted reproduction cycles for diminished ovarian reserve: an analysis of cycles in the United States from 2004 to 2011
Butts SF, Owen C, Mainigi M, Senapati S, Seifer DB, Dokras A. Assisted hatching and intracytoplasmic sperm injection are not associated with improved outcomes in assisted reproduction cycles for diminished ovarian reserve: an analysis of cycles in the United States from 2004 to 2011. Fertility And Sterility 2014, 102: 1041-1047.e1. PMID: 25086790, PMCID: PMC4184996, DOI: 10.1016/j.fertnstert.2014.06.043.Peer-Reviewed Original ResearchMeSH KeywordsChi-Square DistributionEmbryo Culture TechniquesEmbryo TransferFemaleHumansInfertility, FemaleLive BirthLogistic ModelsOdds RatioOvarian ReservePregnancyPregnancy RatePrimary Ovarian InsufficiencyRegistriesRetrospective StudiesRisk FactorsSperm Injections, IntracytoplasmicTime FactorsTreatment OutcomeUnited StatesConceptsDiminished ovarian reserveIntracytoplasmic sperm injectionElevated FSHLive birthsOvarian reserveART cyclesSperm injectionAssisted Reproductive Technology Clinic Outcome Reporting System databaseClinical pregnancy rateRetrospective cohort studyLive birth rateReproductive technology outcomesAssisted reproduction cyclesCombination of ICSIReporting System databaseCohort studyPrimary diagnosisImproved outcomesPregnancy rateMAIN OUTCOMELower oddsDiminished oddsFSHOnly indicationTechnology outcomes
2012
Diagnosis and treatment of diminished ovarian reserve in assisted reproductive technology cycles of women up to age 40 years: the role of insurance mandates
Butts SF, Ratcliffe S, Dokras A, Seifer DB. Diagnosis and treatment of diminished ovarian reserve in assisted reproductive technology cycles of women up to age 40 years: the role of insurance mandates. Fertility And Sterility 2012, 99: 382-388.e7. PMID: 23102859, PMCID: PMC3561490, DOI: 10.1016/j.fertnstert.2012.09.026.Peer-Reviewed Original ResearchConceptsLive birth rateAge 40 yearsART cyclesART coverageElevated FSHOvarian reserveTreatment outcomesReproductive technology treatment outcomesSpecific infertility diagnosisState insurance coverageReproductive technology cyclesDiminished ovarian reserveProportion of cyclesCross-sectional studyBirth rateReporting System databaseInsurance mandatesMix of patientsProvider factorsInfertility diagnosisMAIN OUTCOMEFSHSignificant associationTreatment prognosisAdditional studies
2011
Strategic planning is long overdue and could mitigate long-term complications that result from delayed diagnosis of primary ovarian insufficiency
Seifer DB. Strategic planning is long overdue and could mitigate long-term complications that result from delayed diagnosis of primary ovarian insufficiency. Fertility And Sterility 2011, 95: 1898. PMID: 21444076, DOI: 10.1016/j.fertnstert.2011.03.008.Peer-Reviewed Original ResearchMeSH KeywordsDelayed DiagnosisDiagnostic Techniques, Obstetrical and GynecologicalFemaleGynecologyHealth Planning GuidelinesHumansPrimary Ovarian InsufficiencyTime Factors